Depression in People Living with HIV/AIDS (PLWHA) Receiving Antiviral Regimens
Depression in People Living with HIV/AIDS (PLWHA)
Keywords:
people living with HIV/AIDS (PLWHA), antiviral (HIV) drug, 9Q questionnaire, depressionAbstract
People living with HIV/AIDS (PLWHA) should receive antiretroviral therapy (ART) due to long life expectancy. Rilpivirine (RPV), one of the commonly used ARTs, can cause depression as a side effect. This study aim was to determine depression risk comparison between PLWHA receiving RPV-containing regimen and other regimens. A cross-section study compared the prevalence of depression in both groups by using 9Q questionnaire. Between 1 January-30 April 2020, 336 patients were enrolled in this study. Mean age was 39.5 years and 201 patients (59.8%) were male. Duration of HIV infection was 7.42 years. There were 96 patients received RPV-containing regimen and 240 patients received other regimens. The median 9Q in RPV-containing regimen group was two scores and other regimens group was three scores (p = 0.252). The prevalence of depression was 20.7% (score ≥ 7). Associated risk factors were age ≤ 35 years (adj OR 2.01, 95% CI 1.14-3.57, p = 0.016), history of tuberculosis infection (adj OR 2.02, 95% CI 1.01-4.05, p = 0.046). Depression is common in PLWHA who receiving ART therefore 9Q questionnaire should be assessed in all patients especially for patients age ≤ 35 years or history of tuberculosis infection for depression treatment to improve their quality of life.
References
2. Global information and education on HIV and AIDS in Thailand [online]. 2018 [cited 2020 Feb 24]. Available from: https://www.avert.org/professionals/hiv-around-world/asia-pacific/thailand
3. Gueler A, Moser A, Calmy A, Gunthard HF, Bernasconi E, Furrer H, et al. Life expectancy in HIV-positive persons in Switzerland:Matched comparison with general population.AIDS 2017;31(3):427-36.
4. Teeraananchai S, Chaivooth S, KerrS J, Bhakeecheep S, Avihingsanon A, Teeraratkul A, et al. Life expectancy after initiation of combination antiretroviral therapy in Thailand. AntivirTher 2017;22(5):393-402.
5. Department of Disease Control of Thailand, Ministry of Public Health. Thailand National Guidelines on HIV/AIDS Treatment and Prevention 2017. Bangkok: Department of Disease Control of Thailand, Ministry of Public Health; 2014.
6. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents [online]. 2018 [cited 2019 Mar 2]. Available from: http://www. aidsinfo.nih.gov/ContentFiles/AdultandAdolescent
GL. pdf
7. Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr 2012;60(1):33-42.
8. Kongsuk T, Kittirattanapaiboon P, Kenbubpha K, Sukawaha S, Leejongpermpoon J. The prevalence of major depressive disorders in Thailand: Results from the epidemiology of mental disorders national survey 2008. Proceedings of WPA Section on Epidemiology and Public Health-2010 Meeting Prediction in Psychiatric Epidemiology from Childhood and Adolescence to Adulthood; 2010 Jul 11-14; Lisbon Portugal.
9. Department of Mental Health, Ministry of Public Health. Report on access to services for patients with major depressive disorder [online]. 2019 [cited 2020 Feb 24]. Available from: http://www.thaidepression.com/www/report/main_report/pdf/ahb-11-19_mix_HDC.pdf
10. Nanni MG, Caruso R, Mitchell AJ, Meggiolaro E, Grassi L. Depression in HIV infected patients: A review. Curr Psychiatry Rep 2015;17(1):530-4.
11. Katon W. The impact of depression on workplace functioning and disability costs. Am J Manag Care 2009;15(Suppl 11):s322-7.
12. Uthman OA, Magidson JF, Safren SA, Nachega JB. Depression and adherence to antiretroviral therapy in low-, middle-and high-income countries: A systematic review and meta-analysis. Curr HIV/AIDS Rep 2014;11(3):291-307.
13. Oluboka OJ, Katzman MA, Habert J, Mclntosh D, MacQueen GM, Milev RV, et al. Functional recovery in major depressive disorder: Providing early optimal treatment for the individual patient. Int J Neuropsychopharmacol 2018;21(2):128-44.
14. Bhatia MS, Munjal S.Prevalence of depression in people living with HIV/AIDS undergoing ART and factors associated with it. J ClinDiagn Res 2014;8(10):WC01-4.
15. Jiranukool J, Kotputorn N, Sirisanokaeo T. Prevalence of psychiatric disorders, gender differences and a comparison between depressive or anxiety disorders and adjustment disorders among Mahasarakham University Students at Psychiatric clinic. J Psychiatr Assoc Thailand 2018;63(3):271-84.
16. Charoensak S, Sittironnarit G, Satra T, Muangpaisan W, Srinontprasert. Prevalence of psychiatric disorders in elderly patients, quality of life of patients and caregivers and their correlated factors. J Psychiatr Assoc Thailand 2018;63(1):89-98.
17. Datta D. Prevalence & determinants of depression in type 2 diabetes patients:Problem in generalization. Indian J Med Res 2011;133(5):555-6.
18. Dasa TT, Roba AA, Weldegebreal F, Mesfin F, Asfaw A, Mitiku H, et al. Prevalence and associated factors of depression among tuberculosis patients in Eastern Ethiopia. BMC Psychiatry 2019;19(1):82-6.
